Details for Patent: 9,364,458
✉ Email this page to a colleague
Which drugs does patent 9,364,458 protect, and when does it expire?
Patent 9,364,458 protects VANRAFIA and is included in one NDA.
This patent has twenty patent family members in eighteen countries.
Summary for Patent: 9,364,458
| Title: | Stabilized pharmaceutical dosage forms comprising atrasentan |
| Abstract: | The present disclosure relates to: (a) stabilized pharmaceutical dosage forms comprising atrasenstan, or a pharmaceutically acceptable salt thereof, and, optionally, another therapeutic agent; (b) methods of using such pharmaceutical dosage forms to treat nephropathy, chronic kidney disease, and/or other conditions; (c) kits comprising such pharmaceutical dosage forms and, optionally, a second pharmaceutical dosage form comprising another therapeutic agent; (d) methods for the preparation of such pharmaceutical dosage forms; and (e) pharmaceutical dosage forms prepared by such methods. |
| Inventor(s): | Ye Huang, Andrew K. Koski, Katherine E. Peterson |
| Assignee: | AbbVie Inc |
| Application Number: | US14/324,603 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Device; Dosage form; |
Drugs Protected by US Patent 9,364,458
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | VANRAFIA | atrasentan hydrochloride | TABLET;ORAL | 219208-001 | Apr 2, 2025 | RX | Yes | Yes | 9,364,458 | ⤷ Start Trial | Y | TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,364,458
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2014287496 | ⤷ Start Trial | |||
| Canada | 2916033 | ⤷ Start Trial | |||
| Chile | 2016000027 | ⤷ Start Trial | |||
| Chile | 2016000788 | ⤷ Start Trial | |||
| China | 105517541 | ⤷ Start Trial | |||
| Costa Rica | 20160037 | ⤷ Start Trial | |||
| Dominican Republic | P2016000003 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
